Komori
General Meetings of Shareholders4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Notice of Convocation of the 150th Ordinary General Meeting of Shareholders and General Meeting Materials

The company notified shareholders of the holding of the 150th Annual General Meeting of Shareholders and the submission of 5 proposals: dividends, the election of directors, the election of a substitute director serving as an Audit and Supervisory Committee Member, and the payment of bonuses to directors. Some director candidates will change, and the number of directors other than those serving as Audit and Supervisory Committee Members is scheduled to decrease from 10 to 8.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (150th)
2026
Jun 24
Date and time(Wednesday), 10:00 a.m. (registration scheduled to open at 8:50 a.m.)28 days from this disclosure to the meeting
Matters for resolution5 items
  1. Disposition of surplus

  2. Election of 8 directors, excluding directors who are Audit and Supervisory Committee Members

  3. Election of 3 Directors who are Audit and Supervisory Committee Members

  4. Election of 1 Substitute Director who is an Audit and Supervisory Committee Member

  5. Payment of bonuses to directors, excluding directors serving as Audit and Supervisory Committee Members

Company proposal only. The company states that there was no shareholder proposal.A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee11 candidates in total (8 under Proposal 2 and 3 under Proposal 3). 4 new candidates (2 under Proposal 2 and 2 under Proposal 3); 8 of the 11 candidates are outside directors (5 under Proposal 2 and 3 under Proposal 3)
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (150th)
Date and time24 June 2026 (Wednesday), 10:00 a.m. (registration scheduled to open at 8:50 a.m.)
Matters for resolutionProposal No. 1: Disposition of surplus, Proposal No. 2: Election of 8 directors, excluding directors who are Audit and Supervisory Committee Members, Proposal No. 3: Election of 3 Directors who are Audit and Supervisory Committee Members, Proposal No. 4: Election of 1 Substitute Director who is an Audit and Supervisory Committee Member, Proposal 5: Payment of bonuses to directors, excluding directors serving as Audit and Supervisory Committee Members
Shareholder ProposalNone
Director nominee11 candidates in total (8 under Proposal 2 and 3 under Proposal 3). 4 new candidates (2 under Proposal 2 and 2 under Proposal 3); 8 of the 11 candidates are outside directors (5 under Proposal 2 and 3 under Proposal 3)
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company stated that the number of directors other than those serving as Audit and Supervisory Committee Members will be reduced by 2 to enable more efficient and faster decision-making. The dividend is based on a capital allocation policy of providing attractive returns to shareholders while maintaining a sound financial base. Bonuses will be paid according to the degree of achievement of performance evaluation indicators.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 150th Ordinary General Meeting of Shareholders and General Meeting Materials | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori